uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec in Huntington's Disease Showing Continued Slowing of Disease Progression
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec in Huntington's Disease
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in ?-Gal A Enzyme Activity in Patients with Fabry Disease
